Avapag 20MG (Avatrombopag)

Basic Product Information of Avapag (Avatrombopag) 20mg

How Avapag (Avatrombopag) Works

Avapag contains Avatrombopag, an orally bioavailable, small-molecule agonist of the thrombopoietin (TPO) receptor, also known as c-Mpl, found on the surface of megakaryocyte progenitor cells in the bone marrow. Activating this receptor stimulates the proliferation and differentiation of these progenitor cells into mature megakaryocytes, the cells responsible for producing platelets, thereby increasing platelet production.

A distinguishing feature of Avatrombopag is that it does not compete with the body’s own, naturally occurring TPO for the same binding site on the receptor. Instead, it has an additive effect alongside endogenous TPO on platelet production, an approach also thought to reduce the risk of neutralising antibody formation seen with some earlier platelet-stimulating therapies.

Avapag is taken as an oral tablet with food, with the dosing schedule and duration differing depending on whether it is being used to prepare a chronic liver disease patient for a scheduled procedure, or as ongoing therapy for chronic ITP.

Indications for Avapag (Avatrombopag)

Avapag (Avatrombopag) is indicated for the following conditions:

Benefits of Avapag (Avatrombopag) 20mg

How to Take Avapag (Avatrombopag)

Monitoring and Dosage Adjustments

Regular monitoring is essential throughout Avapag treatment. For the chronic liver disease indication, your physician will check your platelet count before starting treatment and again on the day of your scheduled procedure. For chronic ITP, platelet counts are checked regularly, generally every 2 weeks during dose adjustment, to guide dose increases, decreases, or discontinuation as detailed above. Monitoring also includes assessment for signs of blood clots, particularly in patients with chronic liver disease. Report any leg swelling or pain, sudden breathlessness, chest pain, abdominal pain, or unusual bruising or bleeding to your doctor promptly.

Drug Interactions and Important Information

Avatrombopag is metabolised primarily by CYP2C9 and CYP3A4. Concomitant use of moderate or strong dual inhibitors of both CYP2C9 and CYP3A4 may increase Avatrombopag exposure; discuss any such medications with your physician before starting treatment. Because Avapag is highly protein bound (approximately 96%), caution is advised with other highly protein-bound medications.

Inform your physician of any personal or family history of blood clots before starting treatment, particularly if you have chronic liver disease. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Avapag.

Side Effects and Precautions

Who Should Use Avapag (Avatrombopag)?

Avapag is suitable for adult patients with chronic liver disease and thrombocytopenia who are preparing for a scheduled medical or dental procedure, and adult patients with chronic Immune Thrombocytopenia who have not responded adequately to prior treatments such as corticosteroids, immunoglobulins, or splenectomy. It is prescribed by haematologists, hepatologists, and gastroenterologists depending on the underlying condition. A thorough medical assessment including baseline platelet count and a review of thrombotic risk factors is required before initiating treatment.

Manufacturer: Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, haematology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Avapag under cGMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Avapag is one of Everest’s specialty haematology products, offering a bioequivalent alternative to Doptelet at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty medications. We ensure Avapag (Avatrombopag) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Avapag (Avatrombopag) from Mediaid Pharmacy?

Avapag represents a modern, well-tolerated option for patients managing low platelet counts due to chronic liver disease or chronic ITP. As the generic equivalent of Doptelet, it delivers the same active ingredient, Avatrombopag, with the same proven TPO receptor agonist mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under cGMP-compliant standards and distributed globally by Mediaid Pharmacy, Avapag gives patients worldwide access to effective platelet-support therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Avatrombopag option with worldwide delivery, Avapag from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Avapag (Avatrombopag)